Kitov Plans 2016 NDA For Arthritis Combo Drug
This article was originally published in Scrip
Kitov Pharmaceuticals, which went public in the US in November, ended Dec. 15 with a 25.2% stock price gain at $4.47 per share based on positive Phase III results for lead drug candidate KIT-302 and the Israeli company's plans to seek US FDA approval for the treatment of osteoarthritis.
You may also be interested in...
The latest drug development news and highlights from our Performance Tracker.
Nuvation started in 2018 and raised a $275m series A round in 2019. Now it is merging with the EcoR1 Capital-sponsored SPAC Panacea Acquisition Corp. and raising $500m in equity capital.
Public Company Edition: Codiak, Kiromic, Aligos and Opthea have fallen below their initial public offering values, while Tarsus and Praxis are trading higher. Also, 5AM, MPM and Cormorant took biotech SPACs public and Evotec led recent non-IPO financings with a €250m private placement.